ENTITY
BridgeBio Cuts Gene Therapy Budget by Over $50 Million Following Disappointing Early-Phase Data
BridgeBio, gene therapy, budget cut, early-phase data, CAH treatment, BBP-631, congenital adrenal hyperplasia
GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech
GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus
Gilead Sciences and Genesis Therapeutics Collaborate on AI-Driven Small Molecule Drug Discovery
Gilead Sciences, Genesis Therapeutics, AI-driven drug discovery, small molecule therapies, strategic partnership, generative AI, drug development
Novo Nordisk Reports Significant Weight Loss with New Dual-Acting Oral Drug in Early Clinical Trial
Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist
Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients
Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)
Bain Capital Raises $3 Billion for Fourth Life Sciences Fund to Support Innovative Biotech Startups
Bain Capital, Life Sciences Fund, Biotech Startups, Venture Capital, Funding
Gilead and Genesis Therapeutics Partner on AI-Driven Small Molecule Therapies
AI drug discovery, Gilead Sciences, Genesis Therapeutics, small molecule therapies, generative AI, GEMS platform
Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease
Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development
Centessa’s ORX750 Demonstrates Promising ‘Best-in-Class’ Profile in Early Narcolepsy Trial
Centessa Pharmaceuticals, ORX750, narcolepsy, orexin receptor 2 agonist, sleep-wake disorders, clinical trial, Phase 1 data
EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns
Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy